RhoGAPs Attenuate Cell Proliferation by Direct Interaction with p53 Tetramerization Domain

Cell Reports

Volumn 3, Issue 5, 2013, Pages 1526-1538

  Xu, Jie ^a   Zhou, Xiaolin ^a   Wang, Jilin ^a   Li, Zhaoli ^b   Kong, Xuan ^a   Qian, Jin ^a   Hu, Ye ^a   Fang, Jing Yuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN ARHGAP11A; PROTEIN P53; PROTEIN P63; PROTEIN P73; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; DNA; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; PROTEIN BINDING; RHO GTPASE-ACTIVATING PROTEIN; RHO GTPASE-ACTIVATING PROTEIN 15, HUMAN; SMALL INTERFERING RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; ATTENUATION; CELL CYCLE ARREST; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TETRAMERIZATION DOMAIN; TRANSCRIPTION REGULATION; UPREGULATION; CELL CYCLE CHECKPOINT; CHEMISTRY; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; RNA INTERFERENCE; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; DNA DAMAGE; GTPASE-ACTIVATING PROTEINS; HUMANS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84878603920     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.04.017     Document Type: Article

References (40)

1. Aramayo R., Sherman M.B., Brownless K., Lurz R., Okorokov A.L., Orlova E.V. Quaternary structure of the specific p53-DNA complex reveals the mechanism of p53 mutant dominance. Nucleic Acids Res. 2011, 39:8960-8971.
2. Berns A. Cancer: the blind spot of p53. Nature 2010, 468:519-520.
3. Boon L.M., Mulliken J.B., Vikkula M. RASA1: variable phenotype with capillary and arteriovenous malformations. Curr. Opin. Genet. Dev. 2005, 15:265-269.
4. Brandt T., Petrovich M., Joerger A.C., Veprintsev D.B. Conservation of DNA-binding specificity and oligomerisation properties within the p53 family. BMC Genomics 2009, 10:628.
5. Brooks C.L., Gu W. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2011, 2:456-462.
6. Carr J.R., Kiefer M.M., Park H.J., Li J., Wang Z., Fontanarosa J., DeWaal D., Kopanja D., Benevolenskaya E.V., Guzman G., Raychaudhuri P. FoxM1 regulates mammary luminal cell fate. Cell Rep. 2012, 1:715-729.
7. Charalampopoulos I., Vicario A., Pediaditakis I., Gravanis A., Simi A., Ibáñez C.F. Genetic dissection of neurotrophin signaling through the p75 neurotrophin receptor. Cell Rep. 2012, 2:1563-1570.
8. Ching Y.P., Wong C.M., Chan S.F., Leung T.H., Ng D.C., Jin D.Y., Ng I.O. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J.Biol. Chem. 2003, 278:10824-10830.
9. Cottle D.L., Kretzschmar K., Schweiger P.J., Quist S.R., Gollnick H.P., Natsuga K., Aoyagi S., Watt F.M. c-MYC-induced sebaceous gland differentiation is controlled by an androgen receptor/p53 axis. Cell Rep. 2013, 3:427-441.
10. Davison T.S., Yin P., Nie E., Kay C., Arrowsmith C.H. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome. Oncogene 1998, 17:651-656.
11. el-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1992, 1:45-49.
12. Etienne-Manneville S., Hall A. Rho GTPases in cell biology. Nature 2002, 420:629-635.
13. Fernandez-Escamilla A.M., Rousseau F., Schymkowitz J., Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat. Biotechnol. 2004, 22:1302-1306.
14. Forbes S.A., Bindal N., Bamford S., Cole C., Kok C.Y., Beare D., Jia M., Shepherd R., Leung K., Menzies A., et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011, 39(Database issue):D945-D950.
15. Frank S.A. Genetic predisposition to cancer-insights from population genetics. Nat. Rev. Genet. 2004, 5:764-772.
16. Guerois R., Nielsen J.E., Serrano L. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J.Mol. Biol. 2002, 320:369-387.
17. Hanson S., Kim E., Deppert W. Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization. Oncogene 2005, 24:1641-1647.
18. Hellwinkel O.J., Rogmann J.P., Asong L.E., Luebke A.M., Eichelberg C., Ahyai S., Isbarn H., Graefen M., Huland H., Schlomm T. A comprehensive analysis of transcript signatures of the phosphatidylinositol-3 kinase/protein kinase B signal-transduction pathway in prostate cancer. BJU Int. 2008, 101:1454-1460.
19. Herold T., Jurinovic V., Mulaw M., Seiler T., Dufour A., Schneider S., Kakadia P.M., Feuring-Buske M., Braess J., Spiekermann K., et al. Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20. Genes Chromosomes Cancer 2011, 50:546-558.
20. Jiang S.Y., Ramachandran S. Comparative and evolutionary analysis of genes encoding small GTPases and their activating proteins in eukaryotic genomes. Physiol. Genomics 2006, 24:235-251.
21. Johnstone C.N., Castellví-Bel S., Chang L.M., Bessa X., Nakagawa H., Harada H., Sung R.K., Piqué J.M., Castells A., Rustgi A.K. ARHGAP8 is a novel member of the RHOGAP family related to ARHGAP1/CDC42GAP/p50RHOGAP: mutation and expression analyses in colorectal and breast cancers. Gene 2004, 336:59-71.
22. Kandpal R.P. Rho GTPase activating proteins in cancer phenotypes. Curr. Protein Pept. Sci. 2006, 7:355-365.
23. Kondo S., Barnett G.H., Hara H., Morimura T., Takeuchi J. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 1995, 10:2001-2006.
24. Liao Y.C., Lo S.H. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int. J. Biochem. Cell Biol. 2008, 40:843-847.
25. MacLaine N.J., Hupp T.R. How phosphorylation controls p53. Cell Cycle 2011, 10:916-921.
26. Masse I., Barbollat-Boutrand L., Molina M., Berthier-Vergnes O., Joly-Tonetti N., Martin M.T., de Fromentel C.C., Kanitakis J., Lamartine J. Functional interplay between p63 and p53 controls RUNX1 function in the transition from proliferation to differentiation in human keratinocytes. Cell Death Dis. 2012, 3:e318.
27. Mateu M.G., Fersht A.R. Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain. EMBO J. 1998, 17:2748-2758.
28. Nassar N., Hoffman G.R., Manor D., Clardy J.C., Cerione R.A. Structures of Cdc42 bound to the active and catalytically compromised forms of Cdc42GAP. Nat. Struct. Biol. 1998, 5:1047-1052.
29. Nie Y., Li H.H., Bula C.M., Liu X. Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization. Mol. Cell. Biol. 2000, 20:741-748.
30. Nowsheen S., Aziz K., Panayiotidis M.I., Georgakilas A.G. Molecular markers for cancer prognosis and treatment: have we struck gold?. Cancer Lett. 2012, 327:142-152.
31. Rajagopalan S., Jaulent A.M., Wells M., Veprintsev D.B., Fersht A.R. 14-3-3 activation of DNA binding of p53 by enhancing its association into tetramers. Nucleic Acids Res. 2008, 36:5983-5991.
32. Ridley A.J. Rho proteins and cancer. Breast Cancer Res. Treat. 2004, 84:13-19.
33. Rodriguez M.S., Desterro J.M., Lain S., Lane D.P., Hay R.T. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol. 2000, 20:8458-8467.
34. Seoh M.L., Ng C.H., Yong J., Lim L., Leung T. ArhGAP15, a novel human RacGAP protein with GTPase binding property. FEBS Lett. 2003, 539:131-137.
35. Silvera D., Formenti S.C., Schneider R.J. Translational control in cancer. Nat. Rev. Cancer 2010, 10:254-266.
36. Thebault S., Gilbert D., Machour N., Marvin L., Lange C., Tron F., Charlionet R. Two-dimensional electrophoresis and mass spectrometry identification of proteins bound by a murine monoclonal anti-cardiolipin antibody: a powerful technique to characterize the cross-reactivity of a single autoantibody. Electrophoresis 2000, 21:2531-2539.
37. Tidow H., Melero R., Mylonas E., Freund S.M., Grossmann J.G., Carazo J.M., Svergun D.I., Valle M., Fersht A.R. Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc. Natl. Acad. Sci. USA 2007, 104:12324-12329.
38. Tovchigrechko A., Vakser I.A. GRAMM-X public web server forprotein-protein docking. Nucleic Acids Res. 2006, 34(Web Server issue):W310-W314.
39. Yan Y., Black C.P., Cowan K.H. Irradiation-induced G2/M checkpoint response requires ERK1/2 activation. Oncogene 2007, 26:4689-4698.
40. Yan J., Jiang J., Lim C.A., Wu Q., Ng H.H., Chin K.C. BLIMP1 regulates cell growth through repression of p53 transcription. Proc. Natl. Acad. Sci. USA 2007, 104:1841-1846.